Drug Interactions Database

1418 interactions from BNF 85 - Check your medicines

Source: BNF 85
berotralstat taxanes

increases concentration

Moderate Study
berotralstat temsirolimus

increases exposure

Moderate Study
berotralstat thrombininhibitors

increases concentration

Moderate Study
berotralstat topotecan

increases concentration

Moderate Study
bosentan amlodipine

decreases exposure

Moderate Theoretical
bosentan benzodiazepines

decreases concentration

Moderate Theoretical
bosentan calciumchannelblockers

decreases exposure

Moderate Theoretical
bosentan everolimus

decreases concentration

Moderate Study
bosentan felodipine

decreases exposure

Moderate Theoretical
bosentan guanfacine

decreases concentration

Moderate Theoretical
bosentan lacidipine

decreases exposure

Moderate Theoretical
bosentan lercanidipine

decreases exposure

Moderate Theoretical
bosentan lurasidone

decreases exposure

Moderate Theoretical
bosentan methadone

decreases exposure

Moderate Study
bosentan midazolam

decreases concentration

Moderate Theoretical
bosentan nicardipine

decreases exposure

Moderate Theoretical
bosentan nifedipine

decreases exposure

Moderate Theoretical
bosentan nimodipine

decreases exposure

Moderate Theoretical
bosentan opioids

decreases exposure

Moderate Study
bosentan osimertinib

decreases exposure

Moderate Study
bosentan ripretinib

decreases exposure

Moderate Theoretical
bosentan ruxolitinib

decreases exposure

Moderate Study
bupropion anticholinesterases,centrallyacting

increases exposure

Moderate Study
bupropion atomoxetine

increases exposure

Moderate Study
bupropion eliglustat

increases exposure

Moderate Study
bupropion fesoterodine

increases exposure

Moderate Theoretical
bupropion galantamine

increases exposure

Moderate Study
bupropion pitolisant

increases exposure

Moderate Study
bupropion risperidone

increases exposure

Moderate Study
bupropion tricyclicantidepressants

increases exposure

Moderate Study
bupropion vortioxetine

increases exposure

Moderate Study
calciumchannelblockers bictegravir

increases exposure

Moderate Theoretical
calciumchannelblockers cladribine

increases exposure

Moderate Theoretical
calciumchannelblockers fentanyl

increases exposure

Moderate Theoretical
calciumchannelblockers fostamatinib

increases exposure

Moderate Theoretical
calciumchannelblockers panobinostat

increases exposure

Moderate Theoretical
calciumchannelblockersincreasetheconcentration ofcarbamazepineandcarbamazepine calciumchannelblockers

decreases exposure

Moderate Anecdotal
calciumchannelblockersincreasetheconcentration ofcarbamazepineandcarbamazepine diltiazem

decreases exposure

Moderate Anecdotal
cannabidiol ciclosporin

increases concentration

Moderate Theoretical
cannabidiol clobazam

increases exposure

Moderate Study
cannabidiol everolimus

increases exposure

Moderate Study
cannabidiol tacrolimus

increases concentration

Moderate Theoretical
cannabidiol theactivemetaboliteofbenzodiazepines

increases exposure

Moderate Study
cannabidiol theactivemetaboliteofclobazamandclobazamincreasestheexposuretotheactivemetaboliteofcannabidiol

increases exposure

Moderate Study
cannabidiol valproate

increases risk of increasedaltconcentrations

Moderate Study
capecitabine coumarins

increases effects

Moderate Anecdotal
carbamazepine antifungals,azoles

decreases efficacy

Moderate Theoretical
carbamazepine antipsychotics,secondgeneration

decreases exposure

Moderate Study
carbamazepine atorvastatin

decreases exposure

Moderate Study
carbamazepine coumarins

decreases effects

Moderate Study
Important: This database uses data from the British National Formulary (BNF 85). It is for informational purposes only and is not a substitute for professional medical advice.